New Zealand - English - Medsafe (Medicines Safety Authority)

hospira nz ltd - amiodarone hydrochloride 50 mg/ml - concentrate for infusion - 50 mg/ml - active: amiodarone hydrochloride 50 mg/ml excipient: benzyl alcohol polysorbate 80 water for injection

United States - English - NLM (National Library of Medicine)

cantrell drug company - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone hydrochloride 1.8 mg in 1 ml

Canada - English - Health Canada

teva canada limited - amiodarone hydrochloride - solution - 50mg - amiodarone hydrochloride 50mg - class iii antiarrythmics

Canada - English - Health Canada

fresenius kabi canada ltd - amiodarone hydrochloride - solution - 50mg - amiodarone hydrochloride 50mg - class iii antiarrythmics

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

unimed sdn bhd - amiodarone hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amiodarone hydrochloride, quantity: 200 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; lactose monohydrate; colloidal anhydrous silica; magnesium stearate - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachycardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amiodarone hydrochloride, quantity: 100 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; lactose monohydrate; povidone; colloidal anhydrous silica - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachycardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation.

Malta - English - Medicines Authority

p & d pharmaceuticals limited 38 woolmer way, bordon hampshire gu35 9qf, united kingdom - amiodarone hydrochloride - concentrate for solution for infusion or injection - amiodarone hydrochloride 50 mg/ml - cardiac therapy

Canada - English - Health Canada

sandoz canada incorporated - amiodarone hydrochloride - solution - 50mg - amiodarone hydrochloride 50mg - class iii antiarrythmics

Canada - English - Health Canada

jamp pharma corporation - amiodarone hydrochloride - solution - 50mg - amiodarone hydrochloride 50mg - class iii antiarrythmics